An HIV prevention drug showed protective effects on blood vessels and heart health in rats with diet-induced prediabetes, according to a 2026 study published in Scientific Reports. While Gram Research analysis of this animal research suggests the medication may have cardiovascular benefits beyond treating HIV, human studies are needed before any medical recommendations can be made for people with prediabetes.
Researchers tested an HIV prevention medication on rats with diet-induced prediabetes to see if it could improve heart and blood vessel health. According to Gram Research analysis, the drug appeared to have protective effects on blood vessels and metabolic markers in the animal model. While this is early-stage research using rats rather than humans, the findings suggest that existing HIV medications might have unexpected benefits for people at risk of heart disease from prediabetes. The study was published in Scientific Reports in 2026 and opens new questions about how certain drugs might protect cardiovascular health beyond their original purposes.
Key Statistics
A 2026 animal study published in Scientific Reports found that an HIV-PrEP drug improved vascular health markers in rats with diet-induced prediabetes, suggesting potential cardiovascular protective effects.
Research reviewed by Gram showed that the HIV prevention medication appeared to reduce metabolic damage and inflammation in prediabetic rats, opening new questions about drug repurposing for heart disease prevention.
The Quick Take
- What they studied: Whether an HIV prevention drug could protect blood vessels and heart health in rats that developed prediabetes from eating a high-fat diet
- Who participated: Laboratory rats bred to study disease; some were fed a diet that caused prediabetes, and some received the HIV drug while others did not
- Key finding: The HIV-PrEP drug appeared to improve markers of vascular health and reduce some metabolic problems in rats with diet-induced prediabetes
- What it means for you: This early research suggests HIV medications might protect heart health in people with prediabetes, but human studies are needed before any medical recommendations can be made
The Research Details
Researchers used laboratory rats to test whether an HIV prevention drug (PrEP) could protect blood vessels and heart health in animals with prediabetes. They created prediabetes in some rats by feeding them a high-fat diet, then gave some of these rats the HIV drug while others received no treatment. By comparing the treated and untreated groups, scientists could measure whether the drug had protective effects on blood vessel function and metabolic health markers.
This type of animal research is called a ‘preclinical study’ because it happens in the lab before human testing. Researchers chose rats because their metabolism and disease processes are similar enough to humans to provide useful information, but different enough that findings don’t automatically apply to people. The study measured specific markers of vascular health—essentially checking how well the blood vessels were functioning and whether inflammation or damage had occurred.
Animal studies like this one are important stepping stones in drug development. They help scientists understand whether a medication might have effects beyond its original purpose and whether those effects are safe and meaningful. Testing in rats first is much faster and safer than jumping directly to human trials. If animal research shows promise, it justifies the time and expense of human studies.
This research was published in Scientific Reports, a peer-reviewed journal, which means other scientists reviewed the work before publication. However, the study used animals rather than humans, so results may not directly translate to people. The specific sample size wasn’t provided in the available information, which limits our ability to assess statistical power. Early-stage animal research like this typically has moderate confidence levels and should be viewed as exploratory rather than definitive.
What the Results Show
The HIV-PrEP drug appeared to improve vascular health outcomes in rats with diet-induced prediabetes. Specifically, the medication seemed to protect blood vessel function and reduce some of the metabolic damage that typically occurs when prediabetes develops. The treated rats showed improvements in markers that scientists use to measure inflammation and blood vessel health.
These findings are significant because they suggest the drug might work through multiple pathways to protect heart and blood vessel health. Rather than just treating HIV, the medication appeared to have broader protective effects on the cardiovascular system. The improvements were observed in the context of prediabetes, which is a condition affecting millions of people worldwide and is a major risk factor for heart disease and type 2 diabetes.
Beyond the primary vascular outcomes, the study likely measured other metabolic markers related to blood sugar control and inflammation. These secondary findings help paint a fuller picture of how the drug might protect overall health. The research suggests the protective effects weren’t limited to one specific mechanism but involved multiple ways the drug could benefit cardiovascular health.
This research builds on growing evidence that some HIV medications have effects beyond treating HIV infection. Previous studies have suggested that certain antiretroviral drugs might have anti-inflammatory or metabolic benefits. This study specifically tests whether those benefits extend to protecting heart and blood vessel health in the context of prediabetes, which is a relatively novel application of these medications.
The most important limitation is that this research was conducted in rats, not humans. Rats have different genetics, metabolism, and physiology than people, so findings don’t automatically apply to human health. Additionally, the study used a diet-induced model of prediabetes, which may not perfectly replicate how the condition develops in humans. The specific sample size wasn’t provided, making it difficult to assess whether the results were statistically robust. Finally, this is early-stage research, and much more work would be needed before considering this drug for treating prediabetes in people.
The Bottom Line
This research is too early-stage to recommend the HIV-PrEP drug for prediabetes treatment. Current evidence suggests maintaining established prediabetes management strategies: regular physical activity, healthy eating patterns, weight management, and working with healthcare providers. If human studies eventually confirm these findings, the drug might become an additional option, but that’s years away. Confidence level: Low (animal study only).
People with prediabetes or at risk for heart disease should follow this research but shouldn’t change their current treatment plans based on these findings. Healthcare providers researching cardiovascular complications of metabolic disease should note these results. Pharmaceutical researchers exploring new uses for existing HIV medications should find this work interesting. People currently taking HIV-PrEP medications should not expect cardiovascular benefits beyond what’s already known.
If human studies are eventually conducted, it would likely take 5-10 years before any new treatment recommendations could be made. Animal research typically takes 1-2 years, followed by early human safety studies (2-3 years), then larger efficacy trials (3-5 years). This is a multi-decade process from initial animal findings to clinical practice.
Frequently Asked Questions
Can HIV prevention drugs treat prediabetes?
Animal research suggests HIV-PrEP medications may protect heart health in prediabetes, but human studies haven’t been conducted yet. Current prediabetes treatment focuses on exercise, diet, and weight management. Don’t change medications without consulting your doctor.
Should people with prediabetes take HIV drugs?
No. This is early-stage animal research only. HIV medications carry side effects and are prescribed for specific conditions. Standard prediabetes treatment—lifestyle changes and monitoring—remains the evidence-based approach until human studies confirm benefits.
How long until this becomes a treatment option?
If human studies are eventually conducted, it would likely take 5-10 years minimum before any new treatment recommendations could emerge. Animal findings are preliminary and require extensive human testing before clinical use.
What should I do if I have prediabetes?
Focus on proven strategies: exercise 150 minutes weekly, eat balanced meals with whole grains and vegetables, maintain a healthy weight, and monitor blood sugar with your doctor. These approaches effectively prevent or delay type 2 diabetes development.
Want to Apply This Research?
- Users with prediabetes should track their current management efforts: weekly exercise minutes, daily steps, and periodic blood sugar readings if available. This creates a baseline for comparing any future interventions.
- Focus on evidence-based prediabetes management: aim for 150 minutes of moderate exercise weekly, track carbohydrate intake, and maintain consistent meal timing. These proven strategies should remain the priority while monitoring emerging research.
- Set quarterly check-ins to review blood sugar trends and cardiovascular health markers with your healthcare provider. As new research emerges on HIV medications and metabolic health, discuss whether any new approaches might be appropriate for your situation.
This article discusses early-stage animal research and should not be interpreted as medical advice. HIV-PrEP medications are prescription drugs with specific approved uses and potential side effects. People with prediabetes should continue following their healthcare provider’s recommendations and not change medications based on preliminary animal studies. Always consult with a qualified healthcare provider before making any changes to your treatment plan or medication regimen. This research is exploratory and does not yet support clinical use of HIV medications for prediabetes management.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.